Rigel Pharmaceuticals (RIGL) 10-K2023 FY Annual report

Filed: 5 Mar 24, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: aberrantly, accident, adhere, affiliated, AI, akin, anniversary, art, article, atezolizumab, Australia, aware, bank, banking, BARDA, bear, Biomedical, biostatistical, biotech, Blueprint, bolster, Boston, cabozantanib, ceiling, cemiplimab, CER, CFO, Clawback, clonal, closeout, cloud, coinciding, coinsurance, Colombia, combat, Connecticut, copy, correctly, Council, Counsel, culture, cure, cytopenia, dedifferentiated, Deposit, depository, derogation, diffuse, disagree, disseminated, dissuasive, downstream, DPF, DSMB, DSP, EHD, empower, entail, environmental, environmentally, exacerbate, excise, extraterritorial, FCB, FDIC, feedback, fusion, GAVRETO, geopolitical, gouging, gradual, gravity, hardware, Harmonisation, headquarter, HGG, hire, hiring, HMA, ICT, IDWeek, ILAP, Importantly, incurrence, Indiana, iodine, Iowa, iteration, judgement, lending, macroeconomic, majeure, maker, medullary, merger, methodology, military, misinterpreted, molecularly, monotheraphy, Montana, MSP, myeloproliferative, Nevada, NIS, Nominating, Notably, OES, oluatasidenib, oncogenic, online, Oregon, overlook, PHE, placement, pontine, pool, pose, posture, pralsetinib, Pralsitenib, procedure, processor, proliferation, proportionate, propriety, RDSP, rearranged, receivership, rectification, reinforce, resilience, RET, REZLDHIA, REZLIDIA, Roche, round, sabotage, satisfactorily, sector, selpercatinib, shape, Silicon, Simultaneously, Singapore, slated, sovereign, split, stakeholder, statue, stratification, SVB, temozolomide, Tennessee, terrorist, threatened, thyroid, TIA, timeline, transfection, umbrella, unchanged, undergraduate, undiscounted, unify, unresectable, upcoming, Utah, Valley, verification, Washington, Windsor

Removed: abundance, accessed, afflicted, ALI, AMP, Amsterdam, assuming, AstraZeneca, AZ, background, biomarker, blocked, BMS, bowel, BP, Celgene, coded, conventional, correlate, COVID, death, divergent, donor, Dummer, edema, educating, epithelial, expression, formed, frequent, functional, handle, Harvard, Hgb, HHS, hyperinflammation, idiopathic, IgG, illiquidity, incurring, IRAK, Janssen, jeopardized, Johnson, landlord, licensor, live, macrophage, manageable, Merck, MIT, move, occupy, payer, Pfizer, Pharmaceutica, pioneering, plasma, preferential, pulmonary, purpura, qualification, recoverability, reexamining, reflecting, refundable, reliant, repurposing, responder, resumed, scheduled, screen, screened, Serono, serum, Slough, SOAR, subleased, subtenant, timeframe, timescale, undertaken, unit, unnecessary, unvaried, utility, viability, vivo, warm, Wolfgang

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated RIGL transcripts

RIGL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Raul R. Rodriguez, Chief Executive Officer of Rigel Pharmaceuticals, Inc. (the “Company”), and Dean L. Schorno, Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

The Company’s Annual Report on Form 10-K for the period ended December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of March 5, 2024.


/s/ Raul R. Rodriguez		/s/ Dean L. Schorno
Raul R. Rodriguez Chief Executive Officer		Dean L. Schorno Executive Vice President and Chief Financial Officer

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Rigel Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10- K), irrespective of any general incorporation language contained in such filing.